Two cases of lupus miliaris disseminatus faciei successfully treated with oral tofacitinib

Xinyi ChenDepartment of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaView further author information

Jianjun QiaoDepartment of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaCorrespondence[email protected]
View further author information

References

Al-Mutairi N. Nosology and therapeutic options for lupus miliaris disseminatus faciei. J Dermatol. 2011;38(9):1–2. doi: 10.1111/j.1346-8138.2011.01244.x.
Web of Science ®Google Scholar
Roskoski R.Jr. Properties of FDA-approved small molecule protein kinase inhibitors: a 2023 update. Pharmacol Res. 2023;187:106552. doi: 10.1016/j.phrs.2022.106552.
PubMed Web of Science ®Google Scholar
Damsky W, Wang A, Kim DJ, et al. Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis. Nat Commun. 2022;13(1):3140. doi: 10.1038/s41467-022-30615-x.
PubMed Web of Science ®Google Scholar
Damsky W, Thakral D, McGeary MK, et al. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. J Am Acad Dermatol. 2020;82(3):612–621. doi: 10.1016/j.jaad.2019.05.098.
PubMed Web of Science ®Google Scholar
Gorham NC, Jacobs J, Wu SZ. Response of severe lupus miliaris disseminatus faciei to treatment with ruxolitinib cream. JAMA Dermatol. 2023;159(7):790–791. doi: 10.1001/jamadermatol.2023.0528.
PubMed Web of Science ®Google Scholar